Last update 22 May 2025

[18F]FPyGal

Overview

Basic Info

Drug Type
Chemical drugs, Diagnostic radiopharmaceuticals
Synonyms-
Target
β-galactosidase
Action
modulators
Mechanism
β-galactosidase modulators(Beta-galactosidase modulators)
Therapeutic Areas
Neoplasms
Active Indication
Neoplasms
Inactive Indication
Brain CancerLocally Advanced Malignant Solid NeoplasmNUT midline carcinoma+ [1]
Originator Organization
Universitaetsklinikum Tuebingen
Active Organization
Universitaetsklinikum Tuebingen
Inactive Organization
University Hospital TübingenUniversity Hospital Tübingen
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with [18F]FPyGal
DRKS00022464
/ CompletedPhase 1/2IIT
A phase 1/2, open-label study to assess safety, tolerability, biodistribution, radiation dosimetry and PET imaging characteristics of [18F]FPyGal in comparison to in vitro diagnostic for the assessment of senescence in oncological patients - SenPET
NCT04536454
/ Unknown statusPhase 1/2IIT
A Phase 1/2, Open-label Study to Assess Safety, Tolerability, Biodistribution, Radiation Dosimetry and PET Imaging Characteristics of [18F]FPyGal in Comparison to in Vitro Diagnostics for the Assessment of Senescence in Oncological Patients
100 Clinical Results associated with [18F]FPyGal
Login to view more data
100 Translational Medicine associated with [18F]FPyGal
Login to view more data
100 Patents (Medical) associated with [18F]FPyGal
Login to view more data
100 Deals associated with [18F]FPyGal
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Brain CancerPhase 2
Germany
University Hospital TübingenUniversity Hospital Tübingen
28 Apr 2021
Locally Advanced Malignant Solid NeoplasmPhase 2
Germany
University Hospital TübingenUniversity Hospital Tübingen
28 Apr 2021
NUT midline carcinomaPhase 2
Germany
University Hospital TübingenUniversity Hospital Tübingen
28 Apr 2021
Rectal CancerPhase 2
Germany
University Hospital TübingenUniversity Hospital Tübingen
28 Apr 2021
NeoplasmsPhase 2-
Universitaetsklinikum Tuebingen
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free